Newamsterdam Pharma CO N.V.
Forward trial catalysts linked to NAMS
CSA tracks 2 forward catalysts for Newamsterdam Pharma CO N.V. across 2 assets, spanning Phase 3. The nearest is a readout expected Nov 2026 (month precision). Confidence across its tracked catalysts breaks down as 2 medium. Tracked indications include Atherosclerotic Cardiovascular Disease, Lipidemia.
NAMS in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Newamsterdam Pharma CO N.V. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
3 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| obicetrapib | NCT05202509 catalyst | Phase 3 | Active, not recruiting | 2026-11 | Experimental | NewAmsterdam Pharma | Atherosclerotic Cardiovascular Disease |
| obicetrapib ezetimibe | NCT06305559 catalyst | Phase 3 | Active, not recruiting | 2027-11 | Experimental | NewAmsterdam Pharma | Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic |
| obicetrapib | NCT07219602 | Phase 3 | Active, not recruiting | 2028-03 | Experimental | NewAmsterdam Pharma | Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS) |
| obicetrapib ezetimibe | NCT07219602 | Phase 3 | Active, not recruiting | 2028-03 | Experimental | NewAmsterdam Pharma | Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS) |
Every trial the CSA sample links to NAMS's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →